, 2020 of Baht 41.71 million, an increase by Baht 5.54 million from the same period of previous year which has expenses from feasibility study of new projects which will generate sustainable returns to the

loss and high base of 2Q21 with one-time other income. Revised guidance from rising economic concerns Due to a rising concern on inflation, consumer spending, and continued intense competition, AIS

our customers and generate higher income from both the content as well as subscription in mobile and broadband. Revised down full year guidance following the rising economic risk We revised down the

2nd Quarter 2018 MD&A 11 2019 Guidance Update  Strong industry fundamentals and enhanced visibility of earnings  Outlook for 2019 raised: core EBITDA anticipated to increase 74% on 2017 to $1.75

(2004), dated October 29, 2004 and its amendments. The detail of this transaction is as follows : 1. Transaction Date Wattanapat Samui Hospital is in stage of study for forecasting the Environmental

”) would like to inform the setting up of a new indirect subsidiary company in Indonesia to undertake a feasibility study for the setting up a Mono Ethylene Glycol plant. Details as below: Name of the new

objective is to operate business in online teaching media and education guidance in relation to the preparation for university admission, human resource development and training, investment in other companies

Olefins and Specialty Chemicals businesses are expected to remain weak for the rest of 2019. This changed ecosystem necessitated a comprehensive review of our 2019 EBITDA Guidance. At this juncture, we

EBITDA Guidance. At this juncture, we believe it may be prudent to lower the previous guidance of core EBITDA for 2019 by 10-15%. Our M&A projects continue to drive value-accretive growth. In 2018, the

warrants exercise  LTM 3Q18 Operating Cash Flow of $1,037 million  Net Operating D/E ratio 0.53x; Rating Upgrade to AA- with “Stable Outlook”  2019 Guidance reaffirmed; attractive and accretive production